Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics Inc (RLMD)
:RLMD
RLMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $3.98
Previous CloseN/A
Volume447.03K
Average Volume (3M)189.13K
Market Cap
$21.95M
Enterprise Value-$694.61K
Total Cash (Recent Filing)$20.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 06, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding33,191,624
10 Day Avg. Volume136,605
30 Day Avg. Volume189,126
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.00Price Target Upside49.25% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessNDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.
Market PotentialRelmada announced in-licensing of Trigone's NDV-01 for treating NMIBC, which is seen as a multi-billion opportunity.
Safety And AdministrationNDV-01 was well-tolerated with no treatment-related adverse events greater than grade 1.
Bears Say
Development PrioritizationThe company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.
Pipeline UncertaintyThe company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.
Valuation ConcernsAt this point, the product is not being added into the valuation, and the recommendation remains Market Perform.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was $0.24 and its highest was $3.98 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is $21.95M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.16.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.45.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 33,191,624 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in RLMD
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Relmada Therapeutics demonstrated significant progress in Phase II trials for NDV-01, added promising new product candidates, and improved cash management. However, challenges remain with a decreased cash balance and a notable net loss. Despite these challenges, the advancements in clinical trials and strategic team expansions paint a positive outlook.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$1.00
▲(49.25% Upside)
Technical Analysis
Immuron
―
Bioxcel Therapeutics
―
Citius Pharmaceuticals
―
Hookipa Pharma
―
Athira Pharma
―
Ownership Overview
5.13% Insiders
4.90% Mutual Funds
5.93% Other Institutional Investors
81.02% Public Companies and
Individual Investors